MDT associated with improved progression-free, radiographic progression-free, castration resistance-free survival<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Feb. 9, 2026 (HealthDay News) — For patients with oligometastatic prostate cancer, metastasis-directed therapy (MDT) is beneficial for progression-free, radiological progression-free, and castration resistance-free survival, according to research published in the February issue of The Lancet Oncology<\/em>.<\/p>\n Chad Tang, M.D., from The University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a systematic review and individual patient data meta-analysis to examine the effectiveness of MDT for oligometastatic prostate cancer. A total of 2,975 studies were identified for screening; seven phase 2 studies were included in the review, with 574 participants.<\/p>\n MDT was evaluated in six trials, which randomly assigned 472 patients to MDT plus standard of care (SOC) versus SOC (248 and 224, respectively); the median follow-up was 40.7 months. The researchers observed an association for MDT with improved progression-free survival (trial-level hazard ratio, 0.44; patient-level hazard ratio, 0.45), radiographic progression-free survival (trial-level hazard ratio, 0.60; patient-level hazard ratio, 0.59), and castration resistance-free survival (trial-level hazard ratio, 0.58; patient-level hazard ratio, 0.58). The hazard ratios for the association between MDT and overall survival (0.63 and 0.64 in trial-level and patient-level analyses, respectively) were not significant.<\/p>\n “We hope that this dataset will lay the groundwork for future Phase III trials, which hopefully will show an overall survival benefit for these patients,” Tang said in a statement. “However, what this data does already show is the best evidence to date that MDT significantly benefits patients without adding any notable safety risks.”<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n